Tel.: +49 (0) 391 67 13082, Fax: +49-(0)-391-67-24202
Neuroblastoma triggers an immunoevasive program involving galectin-1-dependent modulation of T cell and dendritic cell compartments
Article first published online: 5 DEC 2011
Copyright © 2011 UICC
International Journal of Cancer
Volume 131, Issue 5, pages 1131–1141, 1 September 2012
How to Cite
Soldati, R., Berger, E., Zenclussen, A. C., Jorch, G., Lode, H. N., Salatino, M., Rabinovich, G. A. and Fest, S. (2012), Neuroblastoma triggers an immunoevasive program involving galectin-1-dependent modulation of T cell and dendritic cell compartments. Int. J. Cancer, 131: 1131–1141. doi: 10.1002/ijc.26498
- Issue published online: 27 JUN 2012
- Article first published online: 5 DEC 2011
- Accepted manuscript online: 22 OCT 2011 11:17PM EST
- Manuscript Accepted: 7 OCT 2011
- Manuscript Received: 11 JUL 2011
- German-Reseach Foundation. Grant Number: DFG (Fe 914/2-1)
- The Medical Faculty
- Otto-von-Guericke University
- Argentinean Agency for Promotion of Science and Technology
- The University of Buenos Aires, Fundación Sales (Argentina), Prostate Cancer Research Foundation (UK) and Mizutani Foundation for Glycoscience (Japan)
- Argentinean National Research Council (CONICET)
- NGFNplus program within the ENGINE consortium. Grant Number: 01GS0899
- T cells;
- dendritic cells
The immunosuppressive strategies devised by neuroblastoma (NB), the most common solid extracranial childhood cancer, are poorly understood. Here, we identified an immunoevasive program triggered by NB through secretion of galectin-1 (Gal-1), a multifunctional glycan-binding protein. Human and mouse NB cells express and secrete Gal-1, which negatively regulates T cell and dendritic cell function. When injected subcutaneously in syngeneic A/J mice, knockdown transfectants expressing low amounts of Gal-1 (NXS2/L) showed reduction of primary tumor growth by 83–90% and prevented spontaneous liver metastases in contrast to NXS2 cell variants (NXS2/H, NXS2 wildtype) expressing high amounts of Gal-1. Splenocytes from mice receiving Gal-1 knockdown NXS2/L cells secreted higher amounts of IFN-γ and displayed enhanced cytotoxic T-cell function compared to NXS2/H or NXS2 controls. Immunohistochemical analysis revealed a six- to tenfold increase in the frequency of CD4+ and CD8+ T cells infiltrating tumors from mice receiving knockdown transfectants. This effect was confirmed by in vitro migration assays. Finally, supernatants of NXS2/H or NXS2 cells suppressed dendritic cell (DC) maturation and induce T cell apoptosis, whereas these effects were only marginal on DCs and T cells exposed to supernatants from NXS2/L cells. These results demonstrate a novel immunoinhibitory role of the Gal-1-glycan axis in NB, highlighting an alternative target for novel immunotherapeutic modalities.
Neuroblastoma (NB) is the most common extracranial solid malignancy in childhood.1 This neuroendocrine tumor arising from neural crest cells is responsible for over 10–15% of pediatric cancer deaths.1 The disease exhibits extreme heterogeneity, resulting in most recent stratification into very low, low, intermediate or high risk.2 NB of lower risk groups occur during the first 18 months of life, and good outcomes are typical after surgery.2 In contrast, high-risk NB, notably characterized by the amplification of NB-derived myelocytomatosis viral related oncogene (N-MYC), is resistant even to the most intensive treatment protocols available.3, 4 This suggests the need of more effective therapeutic strategies targeting nontraditional targets and lacking toxicity for treating high-risk aggressive NB.
The introduction of monoclonal antibodies or chimeric T cells engineered to express chimeric antigen receptors targeting the GD2 antigen together with the implementation of dendritic cell (DC)-based vaccination have validated the critical function of the immune system in promoting NB regression.5 Treatment with IL-2, GM-CSF, CD40 agonists or CTLA-4 blockade, in combination with other traditional approaches, has successfully improved immune effector functions in high-risk NB patient.5, 6 However, the success of these adjuvant immunotherapeutic approaches is hindered by a number of strategies used by tumors or tumor-associated stroma cells to elude immune recognition or thwart immune responses.7 Although well defined in a number of tumor types (e.g. melanoma, ovary cancer and prostate carcinoma),7 the immunoevasive programs displayed by neuroendocrine tumors, particularly NB cells, are still poorly understood.
Galectins, a family of evolutionarily conserved glycan-binding proteins, can control different steps of tumor progression and metastasis including cellular transformation, adhesion, migration, immunity and angiogenesis.8–10 Intracellularly, galectins interact with signaling pathways, whereas extracellularly, these soluble proteins function by cross-linking cell surface glycoconjugates, forming multimeric glycan arrays termed “lattices” and modulating intracellular signalling pathways.11 Research over the past years using experimental models of autoimmunity, inflammation, pregnancy and cancer, has provided proof-of-concept of the pivotal role of galectin-1 (Gal-1), a “proto-type” member of the galectin family, in immune tolerance and homeostasis. In fact, tumor-secreted Gal-1 contributes to the immunosuppressive activity of melanoma,12 Hodgkin lymphoma,13 lung carcinoma14, 15 and pancreatic carcinoma.16 Targeted disruption of Gal-1 gene expression resulted in enhanced T cell-mediated tumor rejection,12 suggesting novel therapeutic opportunities for immunointervention based on the selective blockade of Gal-1-glycan interactions. The cellular and molecular mechanisms underlying these immunosuppressive activities have been recently examined, demonstrating that Gal-1 selectively controls Th1- and Th17-mediated effector functions17 and induces the differentiation of tolerogenic dendritic cells (DCs) through IL-27- and IL-10-dependent pathways.18
Tumor cells from the central nervous system, such as malignant glioma cells, express high amounts of Gal-1, which plays multifaceted roles including modulation of the migratory and invasive capacity of cancer cells, induction of angiogenesis and resistance to chemotherapy.19, 20 Interestingly, NB tumors, particularly those with poor prognosis, also express high levels of Gal-1.21 Blockade of intracellular Gal-1 reduced the migratory and invasive properties of TrkB+ NB cancer cells.21 Moreover, recombinant Gal-1 (rGal-1) restored NB cell invasiveness in these cell cultures suggesting an extracellular action of this lectin in eliciting glycan-dependent signalling processes.21
Based on these observations, we hypothesized that Gal-1 may be secreted from NB cells to dampen host T cell and DC function, thus making these cells unable to eradicate NB. Here, we show that Gal-1 blockade efficiently inhibits primary tumor growth and metastasis through suppression of T cell cytotoxicity, IFN-γ production and DC maturation in a syngeneic mice model of NB. Our results emphasize the role of Gal-1 as a promising therapeutic target in NB, a paradigmatic aggressive tumor of neuroendocrine origin.
Material and Methods
Cell culture and viability assay
Murine NXS2, NXS2/H (Gal-1 high), NXS2/L (Gal-1 low) NB cells were cultured in DMEM (Biochrom AG, Berlin, Germany). Human LAN-1, SK-N-SH, SK-N-SA and Kelly, NB cells were cultured in RPMI (Biochrom AG, Berlin, Germany). All media were supplemented with 10% FCS (PAA Laboratories, Pasching, Austria) and 100 μg/ml penicillin-streptomycin (Biochrom AG, Berlin, Germany). Cells were cultured in monolayer at 37°C and 5% CO2. Viability and proliferation of NXS2, NXS2/H and NXS2/L cells were evaluated by cell counting after staining with Trypan blue (Sigma Aldrich, Germany) and using the CellTiter-Glo® Luminescent Cell Viability Assay, performed according to the manufacturer's protocol (Promega, Mannheim, Germany).
Generation of knockdown NB clones
Murine NXS2 NB cells were transfected with the antisense Gal-1 expression vector p6/G1-As12, 22 using Fugene transfection solution (Roche, Mannheim, Germany). Blasticidine-resistant (5 μg/ml, ICN) stable transfectants were cloned by limited dilution, and six clones were generated. Representative clones with low (NXS2/L) or high (NXS2/H) Gal-1 expression were selected for in vitro and in vivo experiments.
DC isolation, culture and maturation experiments
Mouse bone marrow-derived DCs (mBMDCs) were generated from mouse bones cultured for 7 days according to Lutz et al.23 with minor changes. Briefly, bone marrow from mouse femur and tibia were centrifuged (1200 rpm, 5 min, RT) and resuspended in DC media (1.5 × 106/ml; RPMI, 10% FCS, 1% pencillin-streptomycin, 50 μM β-mercaptoethanol (PAA Laboratories, Pasching, Austria)) supplemented with 20 ng/ml GM-CSF (PeproTech, Hamburg, Germany) for 7 day-culture (10 ml/75 cm2 flask, 37°C, 5% CO2) with medium change on day 3 and 5. On day 7, DCs were resuspended in serum-free condition medium (SFCM) (0.3 × 106/ml) generated from 24-h supernatants of confluent NXS2, NXS2/H and NXS2/L cultures simultaneously with LPS (100 ng/ml; Sigma Aldrich, Germany) to induce DC maturation. mBMDCs were also treated with LPS-containing DCM as a control. After 24 h, expression of I-A/I-K, CD86 were analyzed on CD11c+ DCs by flow cytometry.
Following a standard protocol with minor changes,24 DCs were carefully washed in PBS (pH 7.4 at 4°C) and resuspended in FACS buffer (PBS, 10% FCS) containing PE-labeled CD11c, FITC-labeled I-A/I-K or CD86 monoclonal antibodies (Becton Dickinson GmbH, Heidelberg, Germany). After washing and fixing in FACS buffer containing 4% paraformaldehyde (Roth, Germany), samples were analyzed using a FACS Calibur or FACS LSR Fortessa (Becton Dickinson, Germany) equipped with Cell Quest and FlowJo.
Cytospins and immunohistochemistry
NB cells were centrifuged in cytospins using microscopic glass slides and after drying fixed in acetone (20°C, 20 min). Analysis of Gal-1 expression was performed using rabbit-monoclonal anti-Gal-1 antibody obtained as described elsewhere22 (1:500, 4°C, overnight) and biotinylated anti- rabbit IgG (1 hr, TRIS buffered saline (TBS), pH 7.5, 2.5% goat serum) after blocking (40 min, TBS, 5% goat serum). Staining was accomplished using ABC reagents (30 min), AEC developing kit (10 min) and hematoxylin (5 min). Antibodies and reagents for immunohistochemistry were purchased from Vector Laboratories (Petersbourgh, UK). T cell infiltrate was analyzed in primary tumors (NXS2) using anti-CD8 monoclonal antibody (clone 53-6.7) and anti-CD4 monoclonal antibody (clone RM4-5) (BD Pharmingen, Heidelberg, Germany) as previously described.24, 25 The average percentage of T cells infiltrating tumors was quantified by light microscopy by analyzing 10 power fields at a magnification of 400×.
Western blot analysis
Supernatants from NXS2, NXS2/H and NXS2/L cells were precipitated with acetone (4:1 volume, 1 hr, −20°C). After centrifugation (4000 rpm, 10 min, 4°C), pellets were dried at RT and resuspended in 0.5× PBS (pH 7.4). Tumor cells and T cells were resuspended in NP-40 lysis buffer (40 min, at 4°C), supplemented with a protease inhibitor (10 mM PMSF Carl Roth GmbH, Co. KG, Karlsruhe, Germany). After centrifugation (12,000 rpm, 30 min, 4°C), pellets were resuspendend in PBS (pH 7.4). Protein concentration was measured using Roti-Nanoquant (Carl Roth GmbH, Co. KG, Karlsruhe, Germany). Denatured proteins (90°C, 5 min) were separated by SDS-PAGE (10 μg per lane) and transferred onto nitrocelullose membranes (Amersham, Buckinghamshire, UK). Blots were incubated with anti-Gal-1 rabbit polyclonal antibody22 or anti-GAPDH monoclonal antibody (Santa Cruz Biotechnology, Inc., Heidelberg, Germany) according to the manufacturer's protocol. To analyze apoptosis, we used anti-active caspase 3 rabbit polyclonal antibody (Abcam, Cambrige, UK) (1:1000, 5% milk, TBS, pH 7.4). HPR-labeled anti-rabbit secondary antibody (Dako GmbH, Hamburg, Germany) was added (1:1000, 5% milk, TBS, pH 7.4). Membranes were washed (3×, 10 min, RT) and revealed with ECL™ Detection Reagents (Amersham, Buckinghamshire, UK).
Mice and tumor challenge experiments
Syngeneic female A/J mice (8–10 weeks old) were used (Harlan Laboratories, Berlin, Germany) and housed in our animal facilities (Otto-von-Guericke University, Medical Faculty, Magdeburg, Germany). All experiments included here were conducted according to the German and NIH guide for the care and use of laboratory animals, i.e. “Tierschutzgesetz des Landes Sachsen-Anhalt.” Protocols were previously approved by the Institutional Review Board of Ministry of Saxony-Anhalt (02-928). The well-established NXS2 model for NB24, 25 was chosen to test our hypothesis. Briefly, primary tumors were induced by injection of NXS2, NXS2/H or NXS2/L NB cells (2 × 106 in 100 μl DMEM, s.c., left flank). Primary tumor growth was analyzed by micro caliper measurements, and tumor volume was calculated as follows (length × width2)/2. When primary tumors of control mice reached an average volume of 300–500 mm3 (after 13–16 days), tumors of all mice were surgically removed and their weights were determined. Tumor specimens were stored at −80°C for further analysis.
Splenocytes were isolated from the spleens under sterile conditions and cultured in RPMI (PAA Laboratories, Pasching, Austria) (10% FCS, 100 μg/ml penicillin-streptomycin, 50 μM β-mercaptoethanol, 100 IU/ml IL-2) in the presence of irradiated (30 Gy, 10 min) NXS2 NB cells (100:1) for 7 days. Then, lysis of NXS2-target cells was determined using a standard 51Cr-release assay.24, 25
IFN-γ secretion assay
IFN-γ secretion was measured using a commercial ELISA kit (Becton Dickinson GmbH, Heidelberg, Germany) in the supernatants of splenocytes previously cultured in the presence of irradiated, inactivated NXS2 cells at different time points. These experiments were performed in triplicates.
T cell isolation, migration and annexin V staining
T cells were isolated from the spleens using the Pan T cell isolation kit MACS (Miltenyi Biotec, Bergisch-Gladbach, Germany). Staining and separation were performed according to the manufacturer's protocol. CD3+ T cells were then incubated for 24 hr in NXS2, NXS2/H or NXS2/L SFCM. T cell migration assay was conducted using a two-compartment Boyden chamber system. Isolated CD3+ T cells were loaded into a 5 mm pore polycarbonate transwell insert (Corning Life Science, Amsterdam, Netherlands) (upper chamber, 106 cells in 500 μl RPMI per insert). The lower compartment contained 500 μl SFCM from NXS2, NXS2/H or NXS2/L cells. The negative control was run with RPMI-1640, and the positive control included T cells migrating in the absence of transwell. After 24 hr of incubation, T cells in the lower compartment were counted, and the percentage of T cells migrating (n) was calculated as follows: n/positive control × 100. In another set of experiments, apoptosis of isolated CD3+ T cells was analyzed using a FITC-labeled Annexin V/PI apoptosis detection kit (Bender MedSystems, Vienna, Austria) according to the manufacturer's instructions. Briefly, T cells were washed twice in ice-cold PBS (pH 7.4) and incubated 15 min with FITC-conjugated annexin V and PI staining solution. The percentages of annexin V+ and/or PI+ T cells were analyzed by FACS LSR Fortessa (Becton Dickinson, Germany) equipped with FlowJo.
Data analysis and statistics
Statistical significance between experimental groups was determined using the nonparametrical Kruskal-Wallis test and further analyzed by the Mann-Whitney-U test using Prism 5 software (GraphPad Software, La Jolla, USA). Student's t test was applied to calculate p values for normally distributed data sets. A p value < 0.05 was considered as statistically significant.
Mouse and human NB cells express and secrete Gal-1
Recent evidence indicates that Gal-1 is highly expressed in SY5Y NB cell lines and in tumor tissue from advanced NB patient.21 To investigate whether Gal-1 confers immune privilege to NB cells, we first confirmed and extended these findings by analyzing Gal-1 expression in both human (LAN-1, Kelly, SK-N-AS and SK-N-SH) and mouse (NXS2) NB cell lines (Fig. 1). Immunohistochemical studies on cytospins of single cell suspensions showed that all NB cells and in particular the murine NXS2 cell line express high intracellular levels of Gal-1 protein (Fig. 1a). Western blot analysis of total cell lysates confirmed these findings, showing considerable expression of this lectin in NXS2, SK-N-AS and SK-N-SH cells, and low expression in Kelly and LAN-1 cells (Fig. 1b). To further investigate whether Gal-1 influences immune responses extracellularly, we examined whether this lectin was released by NB cells. Culture of NB cell lines in SFCM for 24 hr and analysis of Gal-1 secretion revealed high amounts of Gal-1 in supernatants of NXS2, SK-N-AS and SK-N-SH cells but reduced Gal-1 secretion from Kelly and LAN-1 cells (Fig. 1b). Our results indicate that Gal-1 is secreted, although at different extents, by NB tumor cells and can, therefore, act as a soluble factor.
Targeted inhibition of Gal-1 gene expression suppresses primary tumor growth and prevents metastases
As Gal-1 expression has been associated with advanced tumor stages, TrkB tyrosine kinase expression and unfavorable prognosis in primary NB,21 we speculated that tumor-secreted Gal-1 may influence NB tumor growth and dissemination in vivo. To address this issue, we transfected murine NXS2 NB cells with Gal-1 antisense cDNA (LAG-1) as described before12 and generated NXS2 clones showing low or high Gal-1 expression (NXS2/L and NXS2/H) for tumor challenge experiments. The expression of Gal-1 in the NXS2/L clone was reduced 80% compared to expression in NXS2/H clone or in wild type nontransfected NXS2 cells (Fig. 2a). Viability and proliferation of NXS2/L and NXS2/H were not substantially different from those showed by the NXS2 (Fig. 2b), confirming that silencing of endogenous Gal-1 did not influence tumor cell growth or apoptosis in vitro. Western blot analysis of total cell lysates from different tissues including muscle, heart, thymus, testis, liver, kidney, lungs, spleen and bone marrow harvested from healthy A/J mice syngeneic to the NXS2 cell clones showed variable, although weak expression of Gal-1 in these tissues, suggesting preferential expression of this lectin in tumor cells in this mouse model (Fig. 2c). To examine whether Gal-1 blockade in the tumor influences its progression, we injected NXS2/L (Gal-1low), NXS2/H or NXS2 (Gal-1high) subcutaneously into A/J mice and assessed primary tumor growth (Fig. 3a). Mice inoculated with the NXS2/L clone showed 83–90% reduction in tumor growth when compared with controls receiving the NXS2/H or NXS2 clones which express high amounts of Gal-1 (Fig. 3b). In addition, weight of surgically removed tumors from NXS2/L-injected mice was 72% lower than tumor weight from mice inoculated with NXS2/H or NXS2 cells (Fig. 3b). In addition, the extent of spontaneous liver metastases was highly dependent on the levels of tumor-specific Gal-1 expression. In this regard, we barely found macroscopic visible metastases in mice receiving NXS2/L transfectants, although metastasis was clearly evident in the NXS2/H group which was comparable to that found in mice receiving NXS2 control tumor cells (Fig. 3c). Thus, endogenous Gal-1 favors tumor growth and metastasis in a syngeneic immunocompetent NB mouse model, suggesting an important role of this lectin in tumor-immune escape.
Gal-1 impairs recruitment and function of T cells in primary NB
Because T cell subsets involved in tumor immunity share all the repertoire of cell surface glycans critical for Gal-1 binding and signalling,17, 26 we next sought to investigate whether Gal-1 promotes tumor progression through selective inhibition of T-cell effector function. Splenocytes from mice inoculated with NXS2/L tumors showed 20–45% higher cytotoxic activity on target cells (82%; E:T 100:1) when compared with splenocytes from mice receiving the same number of NXS2/H or NXS2 (37%; E:T 100:1) (Fig. 4a). This result suggests a critical role for endogenous Gal-1 in impairing cytotoxic T cell function. In addition, the Th1-type cytokine IFN-γ, which is critical for tumor immunoediting,7 was significantly augmented in splenocyte supernatants from mice receiving NXS2/L tumor cells when compared with those obtained from mice inoculated with NXS2 tumor cells (Fig. 4b). Moreover, Gal-1 released by NB cells influenced migration of T cells in in vitro assays. We found a ∼25–40% increase in the percentage of T cells migrating in response to SFCM from NXS/L (73%) when compared with T cells migrating in response to SFCM from NXS2 (48%) or NXS2/H (33%) tumor cell lines (Fig. 5a). These results suggested that release of Gal-1 from NB cells may contribute to impair migration of effector T cells into the tumor parenchyma. This effect was substantiated by an increased recruitment of CD8+ T and CD4+ T cells into the tumor parenchyma in those mice inoculated with tumors secreting low amounts of Gal-1. In fact, a six- to tenfold increase of both T cell subsets was found in tumors excised from NXS2/L mice when compared with NXS2/H or NXS2 tumors (Fig. 5b). In conclusion, Gal-1 secreted by NB impairs different T cell effector functions, including T-cell-mediated cytotoxicity, IFN-γ secretion and T cell recruitment to tumor parenchyma, indicating a major role for this endogenous lectin in favoring tumor-immune evasion in NB. Blockade of this endogenous lectin significantly contributed to overcome tumor-immune escape by augmenting T cell effector function.
NB-derived soluble Gal-1 induces T cell apoptosis and inhibits DC maturation
Because Gal-1 has been reported to modulate T cell survival,26, 27 we analyzed the capacity of NB supernatants corresponding to transfectants secreting low or high Gal-1 levels, to induce apoptosis on splenic T cells. For this, we cultured MACS-sorted CD3+ T cells 24 hr in NXS2/L or NXS2/H SFCM and analyzed annexin V/PI staining as well as caspase 3 expression. We found a 28.15% increase in annexin V+ cells on T cells exposed to NXS2/H SFCM when compared with T cells preincubated with NXS2/L SFCM (Fig. 6a). Additionally, we found enhanced expression of active caspase 3 in T cells exposed to NXS2/H SFCM (Fig. 6b), suggesting that NB cells secrete Gal-1 to dampen effector T cell responses by inducing T cell apoptosis
Because Gal-1 not only inhibits T cell effector functions but also controls the DC compartment,18 we next assessed the effects of NB-derived Gal-1 on DC maturation as an additional inhibitory mechanisms. For this, we cultured bone marrow-derived DC from A/J mice in SFCM obtained from cultures of NXS2/L (Gal-1low) or NXS2/H, NXS2 (Gal-1high) cells. Remarkably, supernatants containing high amounts of Gal-1 (NXS2/H, NXS2) showed substantially lower expression of the activation/maturation markers I-A/I-K (25.8%) and CD86 (25.6%) on CD11c+ BMDCs when compared with CD11c+ BMDCs (57.3% and 50.8%) exposed to normal differentiation and maturation conditions (Fig. 6c). Of note, an increased frequency of CD11c+ BMDCs was positive for I-A/I-K (71%) and CD86 (35.8%) when cultured in the presence of SFCM from NXS2/L (Gal-1low) cells (Fig. 6c). Thus, NB-derived Gal-1 may control effector T cell responses during NB progression either directly via induction of T cell apoptosis or indirectly via promotion of immature or tolerogenic DCs.
The poor prognosis of children diagnosed with stage 4 NB demands a better understanding of NB escape mechanisms as a basis for the development of effective immunotherapeutic approaches. Our results identified a novel mechanism of tumor-immune escape in NB mediated by tumor-derived Gal-1, which favors immune cell dysfunction leading to tumor progression and metastasis. The regulatory function of Gal-1 seems to involve T cell apoptosis and the suppression of DC maturation which favor a tolerogenic microenvironment in NB.
Although not extensively studied like other tumor types, it has been proposed that NB suppresses activation and survival of effector T lymphocytes through expression of Fas L,28 downregulation of MHC class I expression29 and surface expression of inhibitory cell surface molecules, such as CTLA-4, B7-H3 and CD200.30–32 Furthermore, NB cells secrete inhibitory molecules targeting monocytes, NK and T cells that are involved in efficient immune cell control, i.e. the MHC class I chain-related gene A protein (sMICA), sHLA-G, the macrophage migration inhibitory factor (MIF) and TGF-β.33–36 Moreover, immune escape mechanisms developed by NB were additionally linked to unfavorable prognostic amplification of N-MYC, which was demonstrated to repress monocyte chemoattractant protein-1/CC chemokine ligand 2 (MCP-1/CCL2) and influence local NKT cell recruitment.37 Recently, the expression of the neurotropin receptor TrkB, also associated with aggressive NB, was found to correlate with intracellular levels of Gal-1 in primary NB.21 Here, we found expression of Gal-1 in additional human (LAN-1, Kelly, SK-N-AS and SK-N-SH) and murine (NXS2) NB cell lines and demonstrated that this soluble lectin is actively secreted by NB cells. To assess the role of Gal-1 in NB-driven immune escape mechanisms, we generated knockdown cells expressing low levels of Gal-1 (NXS2/L). Inoculation of Gal-1 knockdown transfectants into syngeneic immunocompetent A/J mice (H2-KkDd) led to reduced tumor growth and impaired metastatic potential when compared with mice receiving NB cells expressing high amounts of Gal-1 (NXS2, NXS2/H). These results demonstrate for the first time the important role of Gal-1 as a tolerogeneic molecule in NB and are in line with our previous findings on Gal-1-dependent tumor progression.12–14 Importantly, no significant differences in the viability and proliferation of NXS2/L (Gal-1low) and NXS2, NXS2/H (Gal-1high) cells could be observed in vitro, suggesting that fluctuations in the levels of Gal-1 do not affect intrinsic growth or survival of tumor cells. Supporting a role for Gal-1 in mediating NB-induced immunosuppression, T cells from NB tumors expressing low Gal-1 levels showed augmented cytotoxic activity when compared with T cells from mice harboring NB tumors expressing high levels of this lectin. This effect may reflect Gal-1 crosslinking of glycoproteins or glycolipids expressed on T cells including CD43, CD45, CD7 or GM1.38 Moreover, Gal-1 has been shown to block the production of proinflammatory Th1 and Th17 cytokines.22 In our model, T cells from NXS2/L-challenged mice secreted higher levels of IFN-γ than T cells from mice receiving NB tumors expressing high Gal-1 levels. IFN-γ is known to upregulate MHC class I and costimulatory molecules on NB,39 an effect which may unleash presentation of NB-associated antigens to CD4+ type-1 Th1 and CD8+ cytotoxic T cells.40 Interestingly, silencing Gal-1 expression resulted in enhanced T cell migration in vitro and increased CD4+ and CD8+ T cells in the tumor parenchyma, suggesting enhanced recruitment or survival of these cells in primary NXS2/L tumors compared to NXS2 or NXS2/H tumors. In this regard, blockade of Gal-1 has been proposed as adjuvant to classical immunotherapeutic modalities, and different galectin inhibitors have been designed and tested in vitro and in vivo.41–44 Combining Gal-1-specific disaccharides with classical vaccination protocols significantly decreased tumor progression and improved survival in a mice model of breast cancer.45 Hence, the efficiency of recently developed DNA vaccines targeting NB antigens, i.e. tyrosin hydroxylase (TH), disialoganglioside GD-2 or survivin24, 25, 46 might be improved by blocking Gal-1 expression.
Importantly, Gal-1 has been shown to induce growth arrest and apoptosis of activated T cells.26, 27 Here, we confirmed these findings as NB-derived Gal-1 was able to increase phosphatidylserine exposure and induce expression of active caspase 3 on T cells. To further explore the mechanisms underlying the tolerogenic effects of Gal-1 in NB, we next studied the influence of tumor-derived Gal-1 on DC maturation. Immature or tolerogenic DCs actively induce T cell unresponsiveness through different mechanisms involving induction of T cell anergy, secretion of anti-inflammatory cytokines (like IL-10) or induction of FoxP3+ or FoxP3- T regulatory (Treg) cells which in turn block the expansion or activation of antigen-specific T cells.47, 48 Here, supernatants from NXS2 NB cells induced the differentiation of DCs bearing an immature phenotype characterized by reduced surface expression of MHC class I (I-A/I-K) and CD86. Blocking Gal-1 expression on NB cells prevented this effect as supernatant from NXS2/L allowed full maturation of DCs in culture. This result shows that Gal-1 has a direct influence on the maturation state of DCs, resulting in impaired antigen presentation and effector immune responses, as has been demonstrated in other tumor types.49 Immature DCs usually lead to the differentiation and/or expansion of Treg cells which support tumor dissemination. In fact, Treg cell depletion in vivo effectively improved immune responses against NB.50 Notably, a functional cross-talk between Gal-1, IL-27-producing DCs and IL-10 producing Treg cells has recently been demonstrated in different tumor and autoimmune settings.18
In summary, we provide here the first evidence demonstrating a role for Gal-1 as a pivotal regulator of immune response in NB. We found that cancer-derived Gal-1 modulates T cell and DC compartments, resulting in increased tumor growth and metastasis. Thus, Gal-1 represents a novel target, either alone or in combination with other therapeutic modalities, for the treatment of one of the most challenging tumors during childhood.
This study was mainly supported by grants from the German-Reseach Foundation, DFG (Fe 914/2-1) to SF and the Walter-Schulz-Foundation (SF and ACZ). SF further received a price from HEXAL (Barleben, Sachsen-Anhalt). RS received a grant from the Kind-Philipp-Foundation and EB was supported by a training grant from the Medical Faculty, Otto-von-Guericke University. This work was distinguished with the AACR Scholar-in-Training Award for RS. GAR was funded by the Agencia Nacional de Promoción Científica y Tecnológica (FONCYT; Argentina), the University of Buenos Aires, Fundación Sales (Argentina), Prostate Cancer Research Foundation (UK) and Mizutani Foundation for Glycoscience (Japan). MS was supported by the Argentinean National Research Council (CONICET). Further support was provided by the NGFNplus program within the ENGINE consortium to HNL (01GS0899).